No Data
No Data
No Data
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
Hong Kong stock concept tracking | WHO: Summer COVID-19 resurgence is not ruled out, inflow of funds into the biomedical sector (with concept stocks).
WHO: COVID-19 infection rate is soaring in summer, and the possibility of recurrence cannot be ruled out.
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Junshi Bio (01877) has cumulatively repurchased 0.8159 million shares.
Junshi Bio (01877) announced that as of July 31, 2024, the company has successfully gone through the Shanghai Stock Exchange's trading...
Junshi Biosciences (688180.SH): Has repurchased 0.0828% of the shares.
Junshi Bio (688180.SH) announced on July 31st that as of July 31st, 2024, the company has cumulatively repurchased 815,871 shares of its stock through the Shanghai Stock Exchange trading system in a centralized bidding trading method, representing 0.0828% of the total share capital of the company. The highest and lowest repurchase transaction prices were RMB 41.69/share and RMB 29.03/share, respectively, and the total amount paid, excluding transaction fees such as stamp duty and brokerage commissions, was RMB 30,883,207.73.
Junshi Biosciences Gets Europe's Positive Opinion on Toripalimab
No Data